Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 48, 2016, Pages 13726-13731

  Richards, Mark W ^a   Burgess, Selena G ^a   Poon, Evon ^b   Carstensen, Anne ^c,d   Eilers, Martin ^c,d   Chesler, Louis ^b   Bayliss, Richard ^a,e  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Aurora A kinase; Myc; Neuroblastoma; Protein protein interaction; Structural biology

Indexed keywords

ALISERTIB; AURORA A KINASE; N MYC PROTO ONCOGENE PROTEIN; PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TPX2; UNCLASSIFIED DRUG; AZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CD532 COMPOUND; MYCN PROTEIN, HUMAN; POLYUBIQUITIN; PROTEIN BINDING; PYRIMIDINE DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME STABILITY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; UBIQUITINATION; BINDING SITE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; X RAY CRYSTALLOGRAPHY;

AURORA KINASE A; AZEPINES; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; N-MYC PROTO-ONCOGENE PROTEIN; NEOPLASMS; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; POLYUBIQUITIN; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SKP CULLIN F-BOX PROTEIN LIGASES;

EID: 84999188126     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1610626113     Document Type: Article

References (36)

1. Kress TR, Sabò A, Amati B (2015) MYC: Connecting selective transcriptional control to global RNA production. Nat Rev Cancer 15(10):593-607.
2. Wolf E, Lin CY, Eilers M, Levens DL (2015) Taming of the beast: Shaping Myc-dependent amplification. Trends Cell Biol 25(4):241-248.
3. Vennstrom B, Sheiness D, Zabielski J, Bishop JM (1982) Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 42(3):773-779.
4. Ciriello G, et al. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45(10):1127-1133.
5. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
6. Kohl NE, et al. (1983) Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 35(2 Pt 1):359-367.
7. Schwab M, et al. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305(5931):245-248.
8. Nau MM, et al. (1985) L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318(6041):69-73.
9. Soucek L, et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455(7213):679-683.
10. Tu WB, et al. (2015) Myc and its interactors take shape. Biochim Biophys Acta 1849(5):469-483.
11. Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2):193-205.
12. Helander S, et al. (2015) Pre-anchoring of Pin1 to unphosphorylated c-Myc in a fuzzy complex regulates c-Myc activity. Structure 23(12):2267-2279.
13. Jaenicke LA, et al. (2016) Ubiquitin-dependent turnover of MYC antagonizes MYC/PAF1C complex accumulation to drive transcriptional elongation. Mol Cell 61(1):54-67.
14. Fladvad M, et al. (2005) N and C-terminal sub-regions in the c-Myc transactivation region and their joint role in creating versatility in folding and binding. J Mol Biol 346(1):175-189.
15. Pineda-Lucena A, et al. (2005) A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol 351(1):182-194.
16. Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM (2005) The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 9(3):327-338.
17. Welcker M, et al. (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101(24):9085-9090.
18. Adhikary S, Eilers M (2005) Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6(8):635-645.
19. Otto T, et al. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15(1):67-78.
20. Gustafson WC, et al. (2014) Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26(3):414-427.
21. Dodson CA, et al. (2010) Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: Insights into selectivity and drug design. Biochem J 427(1):19-28.
22. Brockmann M, et al. (2013) Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24(1):75-89.
23. Bayliss R, Sardon T, Vernos I, Conti E (2003) Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 12(4):851-862.
24. Bavetsias V, et al. (2010) Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: Lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem 53(14):5213-5228.
25. Gustafson WC, Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 29(9):1249-1259.
26. Barone G, Anderson J, Pearson AD, Petrie K, Chesler L (2013) New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res 19(21):5814-5821.
27. Hill RM, et al. (2015) Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 27(1):72-84.
28. DuBois SG, et al. (2016) Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol 34(12):1368-1375.
29. Burgess SG, Bayliss R (2015) The structure of C290A:C393A Aurora A provides structural insights into kinase regulation. Acta Crystallogr F Struct Biol Commun 71(Pt 3):315-319.
30. Winter G, Lobley CM, Prince SM (2013) Decision making in xia2. Acta Crystallogr D Biol Crystallogr 69(Pt 7):1260-1273.
31. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt4):658-674.
32. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
33. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58(Pt 11):1948-1954.
34. Chen VB, et al. (2010) MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66(Pt 1):12-21.
35. Burgess SG, et al. (2016) Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain. Open Biol 6(7):160089.
36. Burgess SG, et al. (2015) Aurora-A-dependent control of TACC3 influences the rate of mitotic spindle assembly. PLoS Genet 11(7):e1005345.